Ping An Capital, a private equity firm, led a $124m Series funding round C round in Apollomics, a biopharmaceutical company. “Apollomics is focused on a precision medicine approach that targets specific mutations, amplifications and resistance mechanisms to bring transformative therapies to cancer patients. We appreciate the profound level of support and interest we received during this financing and welcome several new investors to our shareholder base. With this infusion of capital, we will continue our ambitious plans to progress our current pipeline and expand our programs globally," Guo-Liang Yu, Apollomics Co-Founder, Chairman and CEO.